Get familiar with our publications, read about our national and international projects, take a look at the awards collection!
On the 23rd of December 2016 a grant agreement was signed for the creation of Genetic Map of Poland, which will be built under the project “ECBiG – European Centre for Bioinformatics and Genomics” that is included on the Polish Roadmap for Research Infrastructures. Project consortium consists of the Institute of Bioorganic Chemistry of the Polish Academy of Sciences, Poznan University of Technology (Institute of Computing Science) and Poznan company Centrum Badań DNA sp. z o.o. The project manager within the work packages assigned to Poznan University of Technology is the director of the Institute of Computer Science Prof. Jacek Błażewicz
Polish Title of PhD Thesis: Bioinformatyczne metody modelowania i weryfikacji hipotezy Świata RNA.
Polish Title: Automatyczne, wysokoprzepustowe modelowanie struktur przestrzennych RNA. Integrowanie informatyki z eksperymentem biochemicznym.
Polish Title: Informatyczne modele i metody w biologii komórkowej
Recombinant viral vectors and virus-like particles are considered the most promising vehicles to deliver antigens in prophylactic and therapeutic vaccines against infectious diseases and cancer. Several potential vaccine designs exist but their cost-effective development cruelly lacks a standardised evaluation system. On these grounds, COMPUVAC is devoted to:
(i) rational development of a novel platform of genetic vaccines
(ii) standardisation of vaccine evaluation.
COMPUVAC assembles a platform of viral vectors and virus-like particles that are among today's most promising vaccine candidates and that are backed up by the consortium's complementary expertise and intellectual property, including SMEs focusing on vaccine development. COMPUVAC recognizes the lack of uniform means for side-by-side qualitative and quantitative vaccine evaluation and will thus standardise the evaluation of vaccine efficacy and safety by using "gold standard" tools, molecular and cellular methods in virology and immunology, and algorithms based on genomic and proteomic information. "Gold standard" algorithms for intelligent interpretation of vaccine efficacy and safety will be built into COMPUVAC's interactive Genetic Vaccine Decision Support System, which should generate:
(i) vector classification according to induced immune response quality, accounting for gender and age
(ii) vector combination counsel for prime-boost immunisations
(iii) vector safety profile according to genomic analysis.
Since one of our "gold standard" antigens is the West Nile virus (WNV) envelope protein, an additional aim of COMPUVAC is to generate a candidate vaccine against WNV. As end products, our vector platform and "gold standard" tools, methods and algorithms will be available to the scientific and industrial communities as a toolbox and interactive database which standardised nature should contribute to cost-effective development of novel vaccines with validated efficacy and safety profile
Completion of the sequencing of the entire human genome and other major technological advances in bioinformatics have opened up a huge range of scientific challenges that will need to be addressed in order to maintain Europe's scientific and commercial competitiveness and effectiveness in this emerging area of healthcare. An FP6 Network of Excellence, BIOPATTERN, has been established to integrate leading institutes around Europe to form a virtual institute for the study of individualised healthcare. The overall grand vision of BIOPATTERN is to integrate the analysis of the nano level bioinformatic data with micro level biosignal data and macro level patient information data in a pan-European cooperative research effort to combat major disease classes. Selected members of BIOPATTERN (University of Nottingham, UK (UoN), University of Florence, Italy (UoF), Katholieke Universiteit Leuven, Belgium (KUL), University College of Borås, Sweden (UCB) and Poznan University of Technology, Poland (PUT) ) will form the core of the BIOPTRAIN EST, the aim of which is to establish a complementary wide-ranging training programme of world-class quality in bioinformatic optimisation algorithms. There are two crucial groupsof beneficiaries:
(i) the next generation of European scientists must be trained to take advantage of the latest advances in bioinformatics with an aim of creating a vibrant, future-proof and self-sustaining research effort;
(ii) benefits from bioinformatics advances worldwide must be targeted to the European citizen ? we cannot dependon research communities based in the USA and elsewhere to meet the specific needs of European healthcare.